Andrew Cuthbertson
Director/Board Member chez ZENYTH THERAPEUTICS LIMITED
Fortune : 13 M $ au 31/03/2024
Profil
Andrew Cuthbertson is currently the Director at CSL Innovation Pty Ltd.
He is also a Non-Independent Non-Executive Director at CSL Ltd., a Non-independent Executive Director at CSL Behring LLC, a Director at the Centre for Eye Research Australia, a Director at the Grattan Institute, and a Council Member at the University of Melbourne.
Previously, he worked as a Senior Scientist at Genentech, Inc. from 1992 to 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CSL LIMITED
0,01% | 16/02/2024 | 70 391 ( 0,01% ) | 13 M $ | 31/03/2024 |
Postes actifs de Andrew Cuthbertson
| Sociétés | Poste | Début |
|---|---|---|
| ZENYTH THERAPEUTICS LIMITED | Director/Board Member | - |
| CSL LIMITED | Director/Board Member | 17/10/2018 |
CSL Behring LLC
 CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Director/Board Member | 01/01/2018 |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | Corporate Officer/Principal | 01/01/2016 |
| Centre for Eye Research Australia | Director/Board Member | 01/03/2017 |
Grattan Institute
 Grattan Institute Miscellaneous Commercial ServicesCommercial Services Grattan Institute develops public policy programs. The private company is based in Carlton, Australia. The CEO of the Australian company is John Daley. | Director/Board Member | 01/01/2019 |
Anciens postes connus de Andrew Cuthbertson
| Sociétés | Poste | Fin |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/1997 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CSL LIMITED | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
CSL Innovation Pty Ltd.
 CSL Innovation Pty Ltd. Pharmaceuticals: MajorHealth Technology CSL Innovation Pty Ltd. develops pharmaceutical products. The firm also develops human antibody inhibitors of the granulocyte-macrophage colony stimulating factor receptor alpha subunit, GM-CSFRa, for potential therapeutic use in inflammatory diseases. The company was founded in 1986 and is headquartered in Richmond, Australia. | Health Technology |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Health Technology |
| Centre for Eye Research Australia | Government |
Grattan Institute
Grattan Institute Miscellaneous Commercial ServicesCommercial Services Grattan Institute develops public policy programs. The private company is based in Carlton, Australia. The CEO of the Australian company is John Daley. | Commercial Services |
